Since p53 signaling inhibits cell proliferation and also suppresses glycolysis, we hypothesized that downregulation of p53 could exacerbate the pathology of PAH, whereas p53 activation may ameliorate PAH. The gene discussed is TP53; the disease is pulmonary arterial hypertension.